Introduction {#sec1}
============

Premature ovarian insufficiency (POI) and infertility are common adverse effects of cancer treatment. Even when ovarian function is maintained, cancer survivors have a lower chance to achieve pregnancy than expected ([@ref4]; [@ref42]). The toxic potential of chemo- and radiotherapy varies based on the agent's type and dose ([@ref32]; [@ref27]). Alkylating agents and radiation to the ovarian field are associated with the highest risk of infertility ([@ref45]; [@ref8]).

Cryopreservation of mature oocytes or embryos are established clinical procedures to preserve fertility in adult patients undergoing cancer treatments ([@ref34]). For women who cannot postpone the start of treatment, ovarian tissue cryopreservation (OTC) is the only remaining option. Post-pubertal, cryopreserved tissue re-transplanted to the patient can restore ovarian function and fertility, with more than 130 live births reported worldwide ([@ref9]). OTC is the only feasible approach for fertility preservation in pre-pubertal girls, for whom retrieval of mature oocytes is not an option ([@ref21]; [@ref43]; [@ref9]; [@ref34]). This approach is, however, still considered experimental. Ovarian tissue stored from pediatric patients has been successfully used for induction of puberty ([@ref49]; [@ref48]). Recently, two reports describe successful pregnancies stemming from transplantation of ovarian tissue collected when the patients were 13 ([@ref7]) and 9 years old ([@ref30]).

The major centers routinely carrying out OTC offer the procedure when the estimated risk of developing POI is greater than 50%, based on the type of disease and treatment ([@ref10]; [@ref43]; [@ref9]; [@ref22]). At diagnosis, most girls are at low/medium risk of infertility and cryopreservation will not be offered. However, some patients will fall in the high-risk category later on due to poor treatment response or disease relapse and will hence be offered OTC after the initiation of treatments ([@ref44]).

A limited number of reports describe the effects of chemotherapy on ovarian follicles in pediatric populations ([@ref29]; [@ref14]; [@ref2]; [@ref13]; [@ref5]; [@ref11]; [@ref12]). A normal density of viable pre-antral follicles has been observed in patients exposed to chemotherapy, compared to non-exposed ones, especially at younger ages ([@ref2]; [@ref13]; [@ref12]). However, [@ref2], [@ref1]) reported a deterioration in follicular ultrastructure in patients exposed to chemotherapy before OTC. We have previously described decreased *in vitro* survival and maturation of ovarian follicles from cancer patients aged 1--35 years exposed to chemotherapy ([@ref5]).

In the present study, we further characterized the effects of exposure to first-line chemotherapy on pre-antral follicles and ovarian stroma in a cohort of girls and young women with cancer.

Materials and Methods {#sec2}
=====================

Study population {#sec3}
----------------

A total of 43 young patients who underwent fertility preservation between 2003 and 2018 were included. The hospital, age, diagnosis, treatment and cumulative doses of alkylating agents and anthracyclines \[cyclophosphamide equivalent doses (CEDs; [@ref19]) and isotoxic dose equivalents (DIE), respectively ([@ref40]) ([Supplementary Materials and Methods](#sup3){ref-type="supplementary-material"})\] are listed in [Table I](#TB1){ref-type="table"}. [Table I](#TB1){ref-type="table"} further indicates the use of samples in the different assays. As the material is very limited and precious, we could not carry out every analysis in all samples. Altogether, 27 of the samples in this study were from the same cohort used in our previous work ([@ref5]).

###### 

**Main clinical characteristics of the study population and type of assays performed for each patient**.

  **Pt**   **Site**   **First-linetreatment**   **TFL**   **Age**   **Dx**   **Assays**                       
  -------- ---------- ------------------------- --------- --------- -------- ------------ --- --- --- --- --- ---
  1        H          31560                     300       7         12       ES           1   1   0   0   0   0
  2        H          3600                      210       11        5        ALL          1   1   0   0   1   0
  3        H          2000                      120       28        1        ALL          1   1   0   0   0   0
  4        H          0                         300       30        6        AML          1   1   0   0   1   1
  5        H          0                         320       44        4        AML          0   0   0   0   0   1
  6        H          20840                     225       55        1        NBL          1   1   0   0   1   0
  7        H          11400                     120       30        2        NBL          1   1   0   0   1   0
  8        H          9496                      260       9         15       ALL          1   1   0   0   0   0
  9        H          6000                      450       26        11       ALL          1   1   0   0   1   0
  10       H          4100                      180       18        15       NHL          1   1   0   0   0   0
  11       H          2000                      120       18        16       ALL          1   1   0   0   0   0
  12       H          10248                     90        17        5        RMS          1   1   1   0   0   0
  13       O          8540                      120       14        10       RMS          1   1   0   1   0   0
  14       O          6200                      300       35        20       NHL          1   1   1   1   1   1
  15       O          4800                      200       21        24       ALL          1   1   0   1   0   1
  16       H          5589                      135       55        3        NBL          0   0   1   0   0   0
  17       H          23676                     360       26        7        ES           0   0   1   0   0   0
  18       H          7332                      240       20        16       RMS          0   0   1   0   0   1
  19       H          1272                      0         8         2        PNET         0   0   1   0   0   0
  20       H          5853                      240       15        16       RMS          0   0   1   0   0   0
  21       H          2100                      0         48        4        NBL          0   0   1   0   0   0
  22       H          5928                      0         26        1        PNET         0   0   1   0   0   0
  23       H          39593                     360       30        11       RMS          0   0   1   0   0   0
  24       H          4000                      150       25        3        NBL          0   0   0   0   0   1
  25       H          1900                      60        11        10       WT           0   0   0   0   0   1
  26       H          0                         0         \-        15       AA           1   1   1   0   0   1
  27       O          0                         0         \-        12       ES           1   1   0   1   1   1
  28       O          0                         0         \-        23       HL           1   1   0   0   1   0
  29       O          0                         0         \-        20       NHL          1   1   0   0   1   0
  30       O          0                         0         \-        16       OS           1   1   0   0   1   0
  31       O          0                         0         \-        14       HL           1   1   1   1   1   0
  32       O          0                         0         \-        24       ES           1   1   0   1   1   1
  33       O          0                         0         \-        15       NBL          1   1   0   0   0   0
  34       O          0                         0         \-        15       NHL          1   1   0   0   0   0
  35       O          0                         0         \-        19       NHL          1   1   1   1   0   1
  36       O          0                         0         \-        22       ALL          1   1   1   1   0   0
  37       T          0                         0         \-        19       ALL          1   1   0   0   0   0
  38       T          0                         0         \-        19       ALL          1   1   0   0   0   0
  39       H          0                         0         \-        3        SCID         0   0   1   0   0   1
  40       H          0                         0         \-        7        AA           0   0   1   0   0   0
  41       H          0                         0         \-        8        CML          0   0   1   0   0   0
  42       H          0                         0         \-        20       PNET         0   0   1   0   0   0
  43       H          0                         0         \-        2        WT           0   0   0   0   0   1

AA, aplastic anemia; ALL, acute lymphoblastic leukemia; AML, acute mieloid leukemia; CED, cyclophosphamide equivalent doses (mg/m^2^); CML, chronic myeloid leukemia; DIE, doxorubicin isotoxic equivalent (mg/m^2^); Dx, diagnosis; ES, Ewing sarcoma; H, Helsinki; HL, Hodgkin lymphoma; NBL, neuroblastoma; NHL, non-Hodgkin lymphoma; O, Oslo; OS, osteosarcoma; PNET, primitive neuroectodermal tumour; Pt, patient; RMS, rhabdomyosarcoma; SCID, severe combined immunodeficiency; T, Tampere; TFL, time from last chemotherapy dose before ovarian tissue cryopreservation; WT, Wilms tumor. 0 = assay not performed; 1 = assay performed.

Ethical approval {#sec4}
----------------

Ovarian tissue samples were donated by fertility preservation patients treated at the Children's Hospital of the University Central Hospital of Helsinki (Finland), the Department of Gynecology of the University Hospital of Tampere (Finland) and the Department of Gynecology of the Oslo University Hospital (Norway). Adult patients from Tampere and Oslo were offered OTC as a part of fertility preservation program, and they signed an informed consent for quality control of ovarian tissue including morphological analysis and *in vitro* culture. Requirements for further ethical licenses were discussed with Oslo University Hospital, Finnish National Supervisory Authority for Welfare and Health and Finnish Medicines Agency. Since all patients had given their written informed consent concerning the use of the material for scientific work, no further ethical permits were required in accordance with the Medial Research Act (488/1999) and Act on the Medical Use of Human Organs, Tissues and Cells (101/2001).

Pediatric patients were included from Children's Hospital in Helsinki where they participated in a fertility preservation research project approved by the Ethics Committee of Helsinki University Central Hospital (license number 340/13/03/03/2015). Written informed consents for pediatric patients were given by their guardians and by all age-appropriate patients..

Ovarian tissue handling {#sec5}
-----------------------

Ovarian cortical tissue was collected from a total of 43 patients ([Table I](#TB1){ref-type="table"}). For 27 patients, tissue was fixed in formalin prior to cryopreservation and used for immunohistochemical processing. For 11 of these patients and 16 others (total 27 patients), frozen thawed ovarian tissue (ca 2 × 3 × 1.5 mm^3^) was fixed in Bouin's solution and used for morphometric evaluation as described earlier ([@ref5]).

Morphometric analysis {#sec6}
---------------------

Two blinded observers evaluated a subset of 10 sections independently and the results showed an inter-observer concordance above 90%. Following this, each observer evaluated half of the study material. Hematoxylin--eosin stained sections were digitalized using a spectral scanner (Vectra 3 system, Perkin Elmer, MA, USA) and every fifth section was evaluated using PannoramicViewer software (3DHistech, Budapest, Hungary). In order to avoid double counting, only follicles with a clear oocyte nucleus were counted and classified according to previously established morphological criteria ([@ref18]): (i) primordial follicles, oocyte surrounded by a single layer of flattened granulosa cells; (ii) intermediary follicles, oocyte surrounded by a single layer of flattened and at least two cuboidal granulosa cells; (iii) primary follicles, oocyte surrounded by one complete layer of cuboidal granulosa cells; and (iv) secondary follicles, oocyte surrounded by more than one layer of cuboidal granulosa cells. Follicle health was assessed based on follicle shape, oocyte nucleus, oocyte cytoplasm and granulosa cells. In particular, a follicle was considered intact if the round shape was preserved, there was no contraction of the cytoplasm, the oocyte nucleus was centrally located, round and not pyknotic, if there was full contact between the oocyte and the surrounding granulosa cells and no eosinophilia of the cytoplasm. Atretic follicles were those with a distorted follicle shape, dislocated or detached granulosa cells, non-circular or pyknotic oocyte nucleus or eosinophilic cytoplasm ([Supplementary Fig. S1](#sup1){ref-type="supplementary-material"}).

Mean follicle diameter and mean oocyte nucleus diameter was recorded for each annotated follicle by taking two perpendicular measurements using the follicle basement membrane or oocyte nuclear membrane as a reference. The arithmetic mean of the two measurements was used for final calculations..

Staining of ovarian tissue sections {#sec7}
-----------------------------------

Fork head box O3A (FOXO3A) analysis was performed in one section 'per' patient in 8 patients (3 treated and 5 untreated) and gammaH2AX (H2A histone family member X phosphorylated on serine 139) analysis in one section 'per' patient in 18 patients (8 untreated and 10 treated). In brief, following antigen retrieval, slides were blocked in 5% BSA and normal donkey serum (S30, EMD Millipore, Darmstadt, Germany) and then incubated in polyclonal rabbit FOXO3A antibody (PA5-27145, Thermo Fisher Scientific, MA, USA), polyclonal rabbit gammaH2AX antibody (ab2893, Abcam, Cambridge, UK) or polyclonal rabbit IgG antibody (ABIN376827, antibodies-online, Aachen, Germany) as negative control overnight at 4°C. Primary antibodies were detected using donkey anti-rabbit Alexa Fluor 555 conjugated antibody (A31572, LifeTech, MA, USA) for 1 h at room temperature. Sections were mounted using VECTASHIELD mounting media with DAPI (H-1200, VectorLabs, CA, USA).

For detection of fibrotic areas in the ovarian stroma, trichrome staining was performed on samples fixed in Bouin's after thawing using trichrome stain kit (ab150686, Abcam, Cambridge, UK) and one section 'per' patient in 12 patients (6 untreated and 6 treated patients). Briefly, tissue sections were incubated in Weigert's iron hematoxylin for 5 min, followed by Biebrich scarlet/acid fuchsin solution for 15 min, phosphomolybdic/phosphotungstic acid solution for 10 min, aniline blue solution for 5 min and acetic acid solution for 3 min before dehydration (95% ethanol and 100% ethanol) and clearing (xylene for 10 min). Tissue sections were mounted using Pertex® (Histolab, Askim, Sweden).

For stromal cell death detection, TUNEL staining assay was carried out (11684795910, Roche, Penzberg, Germany) using freshly formalin-fixed paraffin-embedded samples and one section 'per' patient in 13 patients (6 untreated and 7 treated). In brief, de-paraffinized and rehydrated tissue sections were treated with proteinase K and incubated with TUNEL reaction mixture for 1 h at 37°C. Positive controls were treated with DNase I for 20 min at room temperature prior to TUNEL reaction. Negative controls were incubated without detection enzyme. Samples were mounted using VECTASHIELD Antifade Mounting Medium with DAPI (Vector laboratories, Peterborought, UK).

Details of imaging of stained ovarian tissue sections are given in [Supplementary Materials and Methods](#sup3){ref-type="supplementary-material"}.

Steroid production in culture {#sec8}
-----------------------------

Follicle function was evaluated by measuring steroid hormones in used culture media from ovarian tissue pieces thawed and cultured for 7 days as described earlier ([@ref5]). Concentrations of cortisol, corticosterone, estradiol, androstenedione, 17a-OH-progesterone, dehydroepiandrosterone, dihydrotestosterone, testosterone and progesterone were quantified in media samples from 27 patients on Days 4 and 7 of culture, and in nine blank media samples as controls, using an established ultra-performance liquid chromatography tandem mass spectrometry method ([@ref20]).

Statistical analyses {#sec9}
--------------------

Statistical analyses were performed using the SigmaStat (v 11.00) package (SPSS, Inc., IL, USA), R ([@ref50]) and RStudio program ([@ref51a]) with the packages ggplot2 ([@ref53]), gplots ([@ref52]), reshape2 ([@ref55]) and dichromat ([@ref54]). Mann--Whitney *U* test was used to compare follicle densities, follicle and oocyte nucleus diameters, steroid concentrations, fibrotic areas, TUNEL signal and gammaH2AX foci numbers between the treated and the untreated patient group. Results are shown as medians and interquartile range. Outliers are defined as values that fall more than 1.5 times the interquartile range above the third quartile or below the first quartile and shown as dots in the figures. All values were included in statistical analyses. Chi-Square analysis was used to compare the proportions of different follicle classes in treated and untreated patients. Morphometric analysis data were used to verify correlation between the morphological parameters and age, CED, DIE and steroid concentrations using Spearman's rank correlation. Forward stepwise regression was used for the evaluation of the major predictor when more than one variable correlated with morphological parameters in Spearman's analysis. Differences were considered statistically significant at *P* \< 0.05.

Results {#sec10}
=======

First-line chemotherapy affects follicle density and size {#sec11}
---------------------------------------------------------

Follicular density was evaluated in ovarian samples from 14 treated and 13 untreated cancer patients ([Fig. 1](#f1){ref-type="fig"}). A total of 3154 follicles (2408 in the treated and 746 in the untreated group) were counted. Representative histological images of ovarian tissue samples from both patient groups are shown in [Fig. 1](#f1){ref-type="fig"}. The main clinical data are reported in [Table I](#TB1){ref-type="table"}. The treated patients had received a median cumulative dose of 6100 CED (0--20,840 mg/m^2^) and 205 DIE (90--450 mg/m^2^) and were significantly younger than the patients who were not treated ([Table II](#TB2){ref-type="table"}). The density of atretic primordial and intermediary follicles was higher in treated patients compared to untreated ones ([Table II](#TB2){ref-type="table"}; [Fig. 2A](#f2){ref-type="fig"}). Treated patients also had a significantly lower density of intact primary follicles compared to untreated patients. When the proportions of follicles were compared instead of densities, treated patients were found to have a significantly higher proportion of atretic follicles in all categories ([Fig. 2B](#f2){ref-type="fig"}). The total follicle density did not differ between the treated and the untreated group ([Table II](#TB2){ref-type="table"}).

![**Representative images of ovarian tissue sections**. Hematoxylin--eosin stained ovarian tissue sections from four patients treated with chemotherapy prior to OTC (Patient number 4, 2, 7, 6; clockwise) and four untreated patients (Patient number 31, 34, 28, 29; clockwise).](dez125f1){#f1}

In treated patients, intact and atretic primordial follicle and oocyte nucleus diameters were significantly smaller compared to those of untreated patients ([Fig. 3](#f3){ref-type="fig"}; [Table III](#TB3){ref-type="table"}). Intact intermediary follicles had also a significantly lower follicular diameter in treated patients.

CED was positively correlated with the total density of atretic follicles (i.e. the sum of atretic primordial, intermediary and primary follicles), atretic primordial follicles and atretic intermediary follicles and was negatively correlated with the density of total and intact primary follicles and with the diameter of intact intermediary follicles. DIE was positively correlated with the density of atretic total follicles, atretic primordial and atretic intermediary follicles and was negatively correlated with the density of intact primary follicles. DIE showed also a negative correlation with the follicular and nuclear diameter of intact primordial follicles and with the diameter of intact intermediary follicles. Age was inversely correlated with the density of atretic primordial follicles ([Supplementary Table S1](#sup4){ref-type="supplementary-material"}). Forward stepwise regression analysis showed that among age, CED and DIE, age was the major determinant of atretic total follicle density (*P* = 0.017), atretic primordial follicle density (*P* = 0.026), atretic intermediary follicle density (*P* = 0.010) and of the ratio between growing and total follicles (*P* = 0.024). The diameter of intact intermediary follicles and the density of intact primary follicles were instead mainly influenced by DIE (*P* = 0.024 and *P* = 0.023, respectively).

###### 

**Density of intact and atretic follicles (follicles/mm** ^**3**^ **) in cryopreserved human ovarian tissues from cancer patients untreated and treated with chemotherapy before ovarian tissue cryopreservation**.

                                      **Untreated (n=13)**   **Treated (n=14)**   **P**
  ----------------------------------- ---------------------- -------------------- -------------
  **Age (y) mean± SD**                17.9 ± 3.7             10.2 ± 7.2           **0.007**
  **CED (mg/m^2^)**                   0.0 (0.0)              6100(3200-10536)     **\<0.001**
  **DIE (mg/m^2^)**                   0.0 (0.0)              205 (120-300)        **\<0.001**
  **Total follicle density**          421 (328-708)          764 (168-1,658)      0.452
   Intact follicles                   10.8 (0.0-231)         31.4 (0.0-154)       0.243
   Atretic follicles                  76.1 (34.4-332)        506 (81.6-1,488)     **0.027**
  **Primordial follicle density**     142 (72.1-268)         225 (37.6-850)       0.593
   Intact primordial follicles        105 (52.3-259)         73.0 (19.4-315)      0.511
   Atretic primordial follicles       20.7 (0.0-34.5)        116 (13.4-621)       0.054
  **Intermediary follicle density**   181 (156-462)          410 (137-736)        0.452
   Intact intermediary follicles      136 (74.8-271)         82.9 (0.0-169)       0.138
   Atretic intermediary follicles     49.2 (9.4-183)         308 (41.9-711)       **0.041**
  **Primary follicle density**        22.6 (19.5-43.4)       3.3 (0.0-24.3)       **0.028**
   Intact Primary follicles           20.6 (0.0-30.4)        0.0 (0.0)            **0.005**
   Atretic Primary follicles          0.0 (0.0-21.2)         0.0 (0.0-22.3)       0.935

Data are expressed as median (quartiles), except for age that is expressed as mean (standard deviations). Comparison between untreated and treated subjects are reported. Bold characters emphasize significant P-values.

![**Follicle density is impacted by first-line chemotherapy**. (**A**) Follicle densities of intact and atretic follicles at different stages of development (primordial, intermediary and primary). Atretic intermediary follicles were found to be increased in treated patients, while intact primary follicle density was decreased ^\*^(*P* \< 0.05). (**B**) Percentage of intact/atretic follicles of 14 treated and 13 untreated patients. A significantly higher percentage of atretic follicles of all developmental stages was observed in treated patients ^\*\*\*^(*P* \< 0.001).](dez125f2){#f2}

![**Size of follicle and oocyte nucleus is decreased by first-line chemotherapy**. Box plots representing diameters of different stages of follicles and their oocyte nuclei of treated (*n* = 14; black bars) and untreated (*n* = 13; white bars) patients. Intact and atretic primordial follicles and their oocyte nuclei as well as intact intermediary follicles were significantly smaller in treated patients ^\*^(*P* \< 0.05), while no difference in primary follicle and oocyte nucleus diameters was observed.](dez125f3){#f3}

###### 

**Follicle and oocyte nucleus diameters (μm) of intact and atretic follicles in cryopreserved human ovarian tissues from cancer patients untreated and treated with chemotherapy before ovarian tissue cryopreservation (OTC)**.

                                       Untreated (n=13)   Treated (n=14)     P
  ------------------------------------ ------------------ ------------------ -----------
  **Intact primordial follicles**                                            
   Follicle diameter                   38.7 (35.1-40.0)   33.4 (31.2-36.4)   **0.042**
   Nuclear diameter                    16.8 (14.8-17.3)   15.1 (13.8-15.8)   **0.042**
  **Atretic primordial follicles**                                           
   Follicle diameter                   36.6 (31.3-40.6)   26.9 (23.9-31.5)   **0.017**
   Nuclear diameter                    14.4 (12.3-15.9)   11.2 (9.6-13.1)    **0.043**
  **Intact intermediary follicles**                                          
   Follicle diameter                   39.6 (36.8-43.1)   35.3 (32.1-38.7)   **0.009**
   Nuclear diameter                    15.9 (14.8-17.1)   14.1 (13.3-15.3)   0.081
  **Atretic intermediary follicles**                                         
   Follicle diameter                   34.0 (27.5-36.7)   31.5 (27.1-33.2)   0.336
   Nuclear diameter                    11.9 (10.6-14.1)   11.8 (9.9-14.0)    0.780
  **Intact primary follicles**                                               
   Follicle diameter                   49.3 (41.0-53.5)   42.0 (40.6-43.4)   0.333
   Nuclear diameter                    16.0 (15.5-17.8)   17.9 (17.3-18.5)   0.500
  **Atretic primary follicles**                                              
   Follicle diameter                   47.8 (32.7-52.4)   33.3 (30.1-38.8)   0.177
   Nuclear diameter                    13.1 (10.3-15.0)   11.6 (10.0-13.7)   0.329

Data are expressed as median (quartiles). Comparison between untreated and treated subjects are reported. Bold characters emphasize significant P-values.

No increase in follicle activation in chemotherapy exposed ovarian tissue {#sec12}
-------------------------------------------------------------------------

As a measure of follicle recruitment, i.e. activation of follicle growth, the ratio of intact growing follicles to the total number of follicles was compared between treated and untreated patients. The ratio was significantly reduced in treated patients compared to untreated ones ([Fig. 4A](#f4){ref-type="fig"}), suggesting that there is no increase in the recruitment of primordial follicles but rather a decrease in the number of growing follicles, consistent with the lower density of intact primary follicles observed in the treated group ([Fig. 2A](#f2){ref-type="fig"}; [Table II](#TB2){ref-type="table"}). We further studied follicle activation through FOXO3A immunostaining. Upon follicle activation, transcription factor FOXO3A is relocated from the nucleus to the cytoplasm ([Fig. 4B](#f4){ref-type="fig"}). All intact follicles of good morphology (judged by DAPI staining) had a clear nuclear localization of FOXO3A, suggestive of a dormant stage.

![**Exposure to chemotherapy before ovarian tissue cryopreservation does not increase activation of ovarian follicles**. (**A**) Box plots showing a significantly smaller proportion of growing follicles in ovarian tissue of treated (*n* = 14) and untreated (*n* = 13) patients. For each patient, the number of intact growing (intermediary and primary) follicles was divided by the total number of intact and atretic follicles (primordial, intermediary and primary) ^\*\*\*^(*P* \< 0.001). (**B**) Immunofluorescence of ovarian tissue from a subset of treated (*n* = 3) and untreated (*n* = 5) patients labeled with fork head box O3A (FOXO3A) antibody shows no differences between the two groups. FOXO3A is located in the nuclei of oocytes and granulosa cells of both treated and untreated patients indicating non-activated follicles. Representative images of ovarian tissue sections are shown.](dez125f4){#f4}

###### 

**Steroid hormone concentrations in culture media of ovarian cortical strips from cancer patients untreated and treated with chemotherapy before ovarian tissue cryopreservation (OTC) at Day 4 and at Day 7 of culture**.

  **Hormone (nM)**   **Day 4**         **Day 7**                                                            
  ------------------ ----------------- ------------------- ----------- ------------------ ----------------- -----------
  P4                 13.0 (2.1-25.6)   0.8 (0.2-4.3)       **0.035**   24.6 (5.5-123.3)   3.7 (0.8-16.0)    0.073
  17alphaOHP         0.1 (0.08-0.2)    0.04 (0.0-0.2)      0.3         0.3 (0.1-1.1)      0.2 (0.0-0.7)     0.27
  A                  0.6 (0.3-1.6)     0.2 (0.09-0.3)      **0.021**   1.6 (1.3-3.1)      0.5 (0.2-1.2)     **0.016**
  T                  0.1 (0.03-0.7)    0.01 (0.004-0.04)   **0.002**   0.6 (0.1-1.8)      0.05 (0.02-0.1)   **0.013**
  E2                 0.2 (0.0-1.5)     0.0 (0.0-0.1)       0.058       2.5 (0.2-8.5)      0.1 (0.0-0.5)     **0.048**

P4, progesterone; 17alphaOHP, 17 alpha hydroxyprogesterone; A, androstenedione; T, testosterone; E2, estradiol. P-value refers to the comparison of hormonal concentration in culture media between untreated and treated ovarian cortical strips. Bold characters emphasize significant P-values.

No increase in gammaH2AX expression in ovarian tissues exposed to chemotherapy {#sec13}
------------------------------------------------------------------------------

We evaluated DNA damage in our samples by gammaH2AX immunostaining. Only intact follicles were included in the analysis, as judged by DAPI stained follicle morphology. Our staining showed no difference in the number of gammaH2AX foci in oocyte nuclei from treated compared to untreated patients, suggesting no differences in DNA double-strand breaks between the groups (*P* = 0.416; [Supplementary Fig. S2](#sup2){ref-type="supplementary-material"}).

Ovarian tissue exposed to first-line chemotherapy produces less steroid hormones during culture {#sec14}
-----------------------------------------------------------------------------------------------

For evaluation of follicle function, we quantified production of steroid hormones during culture. Analysis of blank medium samples showed no steroids present in basal medium. Cortisol, corticosterone and dihydrotestosterone were undetectable in all samples. The average concentrations of estradiol, androstenedione, 17a-OH-progesterone, dehydroepiandrosterone, testosterone and progesterone increased over time in culture in both groups of patients, but were generally lower in treated compared to untreated patients ([Table IV](#TB4){ref-type="table"}). In treated patients compared to untreated ones, androstenedione and testosterone concentrations were significantly lower on Days 4 and 7, progesterone was significantly lower on Day 4 and estradiol was significantly lower on Day 7 ([Table IV](#TB4){ref-type="table"}). Steroid concentrations were positively correlated with density of intact and growing follicles at both time points ([Supplementary Table SII](#sup5){ref-type="supplementary-material"}).

First-line chemotherapy affects ovarian stromal tissue {#sec15}
------------------------------------------------------

As a measure of fibrosis in ovarian stroma, we carried out trichrome assay that detects newly formed collagen-rich (fibrotic) connective tissue in blue ([Fig. 5A](#f5){ref-type="fig"}). The stroma of patients exposed to chemotherapy showed significantly larger areas of collagen with a greater intensity compared to untreated patients ([Fig. 5B](#f5){ref-type="fig"}). DNA fragmentation was evaluated by TUNEL staining of ovarian tissue sections. All untreated patients showed low levels of TUNEL staining in the ovarian stroma, while treated patients showed TUNEL positive tissue areas to various degrees ([Fig. 6A](#f6){ref-type="fig"}). Of the seven analyzed treated patients, five showed clear increase in TUNEL signal while two remained similar to untreated patients. When all patients were included in statistical analysis, TUNEL signal showed only borderline increase in treated compared to untreated patients (*P* = 0.07, [Fig. 6B](#f6){ref-type="fig"}). When the two TUNEL-negative treated patient were removed from the analyses, the difference became significant (*P* = 0.004).

![**Exposure to chemotherapy before ovarian tissue cryopreservation increases collagen-rich stromal tissue areas**. (**A**) Representative images of trichrome assay performed on ovarian tissue sections of treated (*n* = 6) and untreated patients (*n* = 6). Newly formed collagen fibers stain in blue. (**B**) Quantification of the blue component shows that the area of positive staining and the signal intensity are increased in ovarian stromal tissue of patients treated with chemotherapy before OTC. Dashed line indicates reference value of control adult ovarian tissue (*n* = 1) ^\*^(*P* \< 0.05), ^\*\*^(*P* \< 0.005).](dez125f5){#f5}

Discussion {#sec16}
==========

First-line chemotherapy is regarded as low risk in terms of gonadotoxicity, and as such, does not represent an indication to perform OTC. This study provides, for the first time, a comprehensive analysis of the effects of first-line chemotherapy on pre-antral follicles and on the stromal compartment in girls and young women 24 years of age and below. We found a higher number of atretic follicles in ovaries exposed to first-line chemotherapy before OTC compared to those who were not. In addition, we found that treated patients had significantly smaller intact follicles in the earliest stages of development (primordial and intermediary). The diameters of untreated follicles and oocyte nuclei were in line with the previously reported normative values ([@ref46]), whereas the diameters in the treated group were substantially smaller. This might suggest that even follicles that escape atresia after chemotherapy exposure exhibit significant morphological alterations that could have functional consequences. In addition to altered morphology, the density of intact primary follicles was significantly reduced in the treated group, possibly indicating a lower *in vivo* developmental potential of the follicles. These data support our previous *in vitro* culture study, where we reported an impairment of the developmental potential of ovarian follicles in samples collected after chemotherapy ([@ref5]).

![**DNA fragmentation in ovarian stromal cells is influenced by first-line chemotherapy**. (**A**) Representative images showing DNA damage in nuclei of stromal cells of untreated and treated patients. As positive control (PC), the tissue section was pre-treated with DNase I. As negative control (NC), no detection enzyme was used. (**B**) Quantification of TUNEL signal in stromal cell nuclei relative to the total nuclear area of the stained tissue sections of untreated (*n* = 6) and treated patients (*n* = 7).](dez125f6){#f6}

We observed that both the cumulative doses of anthracyclines and alkylating agents as well as the patient's age influence the size of intact intermediary follicles and their ability to progress toward the primary stage, with anthracyclines showing an independent effect. In clinical settings, anthracyclines are classified as safe in terms of risk of ovarian insufficiency. [@ref31]) reported that non-growing follicle density was not depleted but even increased in adult women after exposure to anthracyclines as part of the adriamycin, bleomycin, vinblastine and dacarbazine protocol for Hodgkin lymphoma. However, our observation of an adverse effect of anthracyclines in tissues cryopreserved for fertility preservation highlights that other first-line chemotherapeutics than those associated with long-term ovarian toxicity may also have an impact on follicle quality, at least in young patients.

Follicle activation {#sec17}
-------------------

The 'burn-out' mechanism has been proposed as a potential mechanism of chemotherapy-induced infertility in mice ([@ref24]; [@ref38]), bovine ([@ref16]) and human ovary ([@ref26]). Nuclear localization of FOXO3A marks the dormant state of follicles ([@ref28]). All intact primordial follicles in our samples expressed FOXO3A in the nucleus. In addition, we observed a reduced ratio of growing to total follicles in treated *versus* untreated patients, leading us to reject the hypothesis of an increased activation of follicles in treated patients. It should be noted that the time since last treatment varied from 7 to 55 days, which could reduce chances of detecting possible temporary follicle activation.

DNA damage in follicles {#sec18}
-----------------------

We observed a similar amount of gammaH2AX foci in oocyte nuclei between treated and untreated patients. GammaH2AX is one of the first molecules recruited at DNA damage sites during the process of DNA repair. Mouse studies have shown that phosphorylation of H2AX happens in the oocyte nucleus around 10 min after DNA damage ([@ref37]; [@ref23]), reaching a peak after 24 h ([@ref17]; [@ref36]; [@ref39]). Assuming that H2AX follows the same kinetics in human ovaries, we might have failed to detect higher levels, as chemotherapy has been administered 8--55 days before OTC in analyzed treated cases. Alternatively, gammaH2AX might not be a suitable marker for cell death after chemotherapy, which could instead be mediated by oxidative stress or indirectly by stromal damage ([@ref41]).

Follicle function {#sec19}
-----------------

Analysis of media from ovarian cultures showed production of both theca and granulosa cell-specific hormones, with increasing concentrations over time in culture and levels comparable to those produced by cultured ovaries of adult patients ([@ref20]). According to literature, theca and granulosa cells express steroidogenic enzymes from the secondary follicle stage ([@ref3]). In our samples, the number of secondary follicles was very low and steroid production was positively associated with the density of intact intermediary and primary follicles. Very little is known about the steroidogenic activity of pre-pubertal ovaries. However, fetal ovaries are capable of producing estradiol already from the second trimester, i.e. when primordial follicle formation occurs and pre-granulosa cells appear ([@ref15]), suggesting that the steroids detected in our samples could be secreted by pre-antral follicles. Alternatively, somatic cells might acquire steroidogenic potential after exposure to the *in vitro* environment, as previously suggested ([@ref35]). If this is the case, the overall lower steroid concentration in ovarian tissue from treated patients could also be caused by the chemotherapy-induced stromal damage that we observed.

Ovarian stromal cells {#sec20}
---------------------

Analysis of cortical stroma revealed a significant increase in fibrotic area and an increase in DNA damage in treated compared to untreated patients. This finding is supported by other reports showing cortical fibrosis ([@ref51]) and stromal apoptosis ([@ref13a]) in ovarian tissue upon chemotherapy treatment. If stromal cells play a role in steroid production (as suggested by our steroid data), then fibrotic stroma might affect the quality of non-growing as well as early growing follicle.

Limitations {#sec21}
-----------

Our study has limitations. The study population was heterogeneous in terms of age and treatment exposures. Younger age might have contributed to the higher follicle atresia in the treated group. Furthermore, the impact of specific treatments could not be assessed. The limited tissue availability did not allow us to perform all the analyses in all patients and subsets had to be used, lowering the statistical power.

In summary, we demonstrated that exposure to first-line cancer treatment negatively impacts follicle number, follicle morphology, steroid secretion in culture and ovarian stromal compartment. Furthermore, we were able to show that atretic death in primordial follicles rather than ovarian 'burn-out' through follicle activation might be the dominant mechanism of action of ovarian failure following chemotherapy, as has also been suggested by others ([@ref25]; [@ref6]; [@ref33]; [@ref47]).

We observed a significant correlation between the density of atretic follicles and the cumulative exposure to alkylating agents and anthracyclines, which are widely used as first-line therapy in many pediatric solid cancers and hematological malignancies. The combined treatment with both drug types in the majority of the treated patients prevented identification of any drug-specific effects. Our observations suggest that OTC should be performed earlier, before the initiation of any chemotherapy, in order to prevent adverse effects on follicles and stroma. Follow-up investigations should focus on chemotherapy agent-specific effects on human follicles. In addition, assessing treatment effects on pre-pubertal primordial follicles as compared to adult primordial follicles should be considered.
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